After an exceptional response after the EAACI (European Academy of Allergy and Clinicial Immunology) congress in London earlier this summer, where the first results from the 4A-study were made public, it is time for an organizational change. Airsonett will embark upon a change from being a primarily research and development oriented company to a fully fledged commercial company. A change that is absolutely essential for the future success of the company.
Apart from continued sales efforts introducing Opragon® in Sweden and Denmark and the commercial launch of Protexo® in Sweden, UK and Germany, Airsonett will, during the autumn, incorporate two new subsidiaries; one company for each product area – Asthma Treatment and Infection Control. The Asthma Treatment division, will be headed by Dan Kristensson and the Infection Control division, will be headed by Airsonett’s current Director of Sales and Marketing Peter Ekolind. The names of the companies are yet to be decided.
“Incorporation will take place by the year’s end, but the process has already started” says Dan Kristensson, CEO Airsonett AB.
For more information, please contact:
Dan Kristensson, CEO, Airsonett AB,
Phone: +46 (0)431 402531, e-mail firstname.lastname@example.org
Airsonett is a research based medical technology company with a unique technology pioneering the development of non-pharmaceutical treatment of asthma as well as management of airborne bacteria and virus contamination. Airsonett was awarded the title Sweden’s MedTech Company of the Year 2009. www.airsonett.com